Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 6366-6369

  Williamson, Beth ^a   Dooley, Kelly E ^b   Zhang, Yuan ^a   Back, David J ^a   Owen, Andrew ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; ETHAMBUTOL; ISONIAZID; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B1; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B3; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG POTENCY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; UPREGULATION;

CELLS, CULTURED; CYTOCHROME P-450 CYP3A; HEPATOCYTES; HUMANS; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; RIFABUTIN; RIFAMPIN;

EID: 84887463525     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01124-13     Document Type: Article

References (29)

1. World Health Organization. 2012. Global tuberculosis report 2012. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/publications/ global-report/gtbr12-main.pdf.
2. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. 2003. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin. Pharmacokinet. 42:819-850.
3. Martin P, Riley R, Back DJ, Owen A. 2008. Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. Br. J. Pharmacol. 153:805-819.
4. Huisman MT, Smit JW, Crommentuyn KM, Zelcer N, Wiltshire HR, Beijnen JH, Schinkel AH. 2002. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 16:2295-2301.
5. Su Y, Zhang X, Sinko PJ. 2004. Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of saquinavir in Hep G2 cells. Mol. Pharm. 1:49-56.
6. Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD. 2007. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab. Dispos. 35: 1853-1859.
7. Baciewicz AM, Chrisman CR, Finch CK, Self TH. 2013. Update on rifampin, rifabutin, and rifapentine drug interactions. Curr. Med. Res. Opin. 29:1-12.
8. Burman WJ, Gallicano K, Peloquin C. 2001 Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin. Pharmacokinet. 40:327-341.
9. Li AP, Reith MK, Rasmussen A, Gorski JC, Hall SD, Xu L, Kaminski DL, Cheng LK. 1997. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chem. Biol. Interact. 107:17-30.
10. Dooley K, Flexner C, Hackman J, Peloquin CA, Nuermberger E, Chaisson RE, Dorman SE. 2008. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob. Agents Chemother. 52:4037-4042.
11. Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL. 2012. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob. Agents Chemother. 56:4331- 4340.
12. Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL. 2007. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 4:e344. doi:10.1371/journal.pmed.0040344.
13. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven- Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR, Chaisson RE. 2011. Three months of rifapentine and isoniazid for latent tuberculosis infection. N. Engl. J. Med. 365:2155-2166.
14. Dooley KE, Bliven-Sizemore EE, Weiner M, Lu Y, Nuermberger EL, Hubbard WC, Fuchs EJ, Melia MT, Burman WJ, Dorman SE. 2012. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin. Pharmacol. Ther. 91: 881-888.
15. Invitrogen. 2012. Thawing and plating hepatocytes protocol. Invitrogen- Life Technologies, Carlsbad, CA. http://www.invitrogen.com/site/us/en/h ome/References/protocols/drug-discovery/adme-tox-protocols/thawingand- plating-hepatocytes-protocol.html#4.
16. Hewitt NJ, Lechon MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, Guillouzo A, Tuschl G, Li AP, LeCluyse E, Groothuis GM, Hengstler JG. 2007. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab. Rev. 39:159-234.
17. Acocella G. 1978. Clinical pharmacokinetics of rifampicin. Clin. Pharmacokinet. 3:108-127.
18. Skinner MH, Blaschke TF. 1995. Clinical pharmacokinetics of rifabutin. Clin. Pharmacokinet. 28:115-125.
19. Boman G, Ringberger VA. 1974. Binding of rifampicin by human plasma proteins. Eur. J. Clin. Pharmacol. 7:369-373.
20. Ohtsuki S, Schaefer O, Kawakami H, Inoue T, Liehner S, Saito A, Ishiguro N, Kishimoto W, Ludwig-Schwellinger E, Ebner T, Terasaki T. 2012. Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab. Dispos. 40:83-92.
21. Shugarts S, Benet LZ. 2009. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm. Res. 26:2039-2054.
22. Yimer G, Ueda N, Habtewold A, Amogne W, Suda A, Riedel KD, Burhenne J, Aderaye G, Lindquist L, Makonnen E, Aklillu E. 2011. Pharmacogenetic and pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One 6:e27810. doi:10.1371/journal.pone.0027810.
23. Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE. 2012. Pharmacogenomics and individualized medicine: translating science into practice. Clin. Pharmacol. Ther. 92:467-475.
24. Choi MK, Jin QR, Choi YL, Ahn SH, Bae MA, Song IS. 2011. Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions. Biopharmaceut. Drug Dispos. 32:175-184.
25. Chigutsa E, Visser ME, Swart EC, Denti P, Pushpakom S, Egan D, Holford NH, Smith PJ, Maartens G, Owen A, McIlleron H. 2011. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob. Agents Chemother. 55:4122-4127.
26. Smythe W, Khandelwal A, Merle C, Rustomjee R, Gninafon M, Bocar Lo M, Sow OB, Olliaro PL, Lienhardt C, Horton J, Smith P, McIlleron H, Simonsson USH. 2012. A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients. Antimicrob. Agents Chemother. 56:2091-2098.
27. Jindani AMH, Charalambous S, Mungofa S, Zizhou S, van Dijk J, Shepherd J, Phillips P P, Nunn A, Mitchison D, Trial Team RIFAQUIN. 2013. A multicentre randomized clinical trial to evaluate high-dose rifapentine with a quinolone for treatment of pulmonary TB: The RIFAQUIN Trial, abstr 147LB. 20th Conf. Retroviruses Opportun. Infect. (CROI), Atlanta, GA, 3 to 6 March 2013.
28. Boeree MAD, Dawson R, Venter A, du Bois J, Narunsky K, Hoelscher M, Gillespie S, Phillips P, Aarnoutse R. 2013. What is the "right" dose of rifampin?, abstr 148LB. 20th Conf. Retroviruses Opportun. Infect. (CROI), Atlanta, GA, 3 to 6 March 2013.
29. Haenisch S, Laechelt S, Bruckmueller H, Werk A, Noack A, Bruhn O, Remmler C, Casscorbi I. 2011. Down-regulation of ATP-binding cassette C2 protein expression in HepG2 cells after rifampicin treatment is mediated by microRNA-379. Mol. Pharmacol. 80:314-320.